title: [Discovered roles of MLL in pathogenesis of multiple myeloma].
abstract: Multiple myeloma is one of incurable hematological malignancies and targeted therapies for novel oncogenes are to be exploited. Analyses of multiple myeloma patients revealed that HOXA9 was overexpressed in patients lacking known IgH translocation and it was evaluated as a candidate oncogene in multiple myeloma. This overexpression of HOXA9 was supposed to be due to dysfunction of histone methyltransferases (HMT) and mutations in MLL encoding HMT were found. Panobinostat, an HDAC inhibitor is currently undergoing preclinical and clinical evaluation as a novel drug for multiple myeloma. We found that panobinostat suppresses expression of MLL protein through modulation of its stability as well as Hsp90 inhibitor. More precise roles of MLL in pathogenesis of multiple myeloma are to be elucidated.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Imai
authors.forename: Eri
authors.initials: E
authors.lastname: Ohta
mesh_terms: D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D018398:Homeodomain Proteins / Q000235:genetics; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D051788:Myeloid-Lymphoid Leukemia Protein / Q000502:physiology*
chemical_list: D056572:Histone Deacetylase Inhibitors; D018398:Homeodomain Proteins; C097899:homeobox protein HOXA9; D051788:Myeloid-Lymphoid Leukemia Protein